Recent

% | $
Quotes you view appear here for quick access.

Nuvilex, Inc. Message Board

  • trygirl2oo2 trygirl2oo2 Jul 17, 2007 10:17 PM Flag

    for anyone that thought the the test was bias it was not heres the facts

    http://www.cinnergen.com/cinnergen_study_final.html

    Clinical Site and Study Performed by:

    David J. Miller, DO, FAAP

    Director

    Fellow American Academy of Family Practice

    Bucks County Clinical Research, Inc.

    201 Woolston Drive

    Morrisville, Pennsylvania 19067

    215-736-8520 (phone)

    215-736-0240 (facsimile)



    January 12, 2007



    Principal Investigator with the following companies:



    Abbott Laboratories Marion Laboratories Sandoz Glaxo Wellcome

    Sankyo/Upjohn Reed & Carnick Lorex Takeda America

    Kal-Chemie Schering G. D. Seric & Co. Novartis

    Ciba-Geigy Merck, Sharp & Dohme Whitehall Laboratories Hoechst Marion Roussel

    Hoffmah/LaRoche Pfizer Chiesi Pharmaceuticals TAP Holdings

    Eli Lilly 3M Pharmaceuticals Lederle Asta Medica

    Parke-Davis Smith Kline Rhone-Poulenc Rorer Astra Zeneca

    Glaxo ICI Pharmaceuticals Bristol Myers Squibb Genomics Collaborative

    McNeil Searle Bayer Pharmaceuticals Ortho-McNeil

    Wyeth Ayerst Schwartz-Pharma Johnson & Johnson Aventis



    Background:

    The purpose of this study was to determine Cinnergen�sTM efficacy in a controlled Phase I study. Upon completion of the case study on CinnergenTM, it was shown to have a positive effect on lowering blood sugar in a Type II Diabetic.

    To determine the effects of CinnergenTM on Type I and Type II Diabetics with regard to lowering and regulating blood sugar levels.
    All 50 patients completed a survey questionnaire upon completion of the study regarding Quality of Life Issues.


    Research Design and Methods:

    Study Subjects

    There were a total of 50 randomized patients consisting of men and women between the ages of 29 and 84 with Type I Diabetes or Type II Diabetes. During the study, Twenty-five (25) patients received CinnergenTM and twenty-five (25) patients received a placebo.

    The investigator and all personnel involved in the study were blinded to assure accuracy.

    Patients signed an informed consent. All results are based upon patient�s compliance and completion of the study.

    All 50 patients were current patients of Pennsbury Family Medical Centers.

    Patients who complete the study were given the option of continuing on CinnergenTM for an additional 3 months free of charge. After the three (3) months, patients may continue on CinnergenTM for a nominal fee.



    Study Design

    This study is a double blind phase 1, 3-month (90 day) trial performed at Bucks County Clinical Research by principal investigator Dr. David J. Miller and staff.

    Please see curriculum vitae of Dr. David J. Miller, DO, FAAP, Richard M. Goldfarb, MD, FACS, and brochure of Bucks County Clinical Research as a center of excellence and innovation in clinical research by visiting the website at www.bccrinc.com.

    Bucks County Clinical Research is an FDA-approved and regulated clinical facility, which meets the highest standards for studying prescription and non-prescription medications. Current on-going studies include:

    SortNewest  |  Oldest  |  Most Replied Expand all replies